Growth Metrics

Incyte (INCY) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -10.84%
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 26.38%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -46.86%
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 13.80%
7 Evaxion A 64.16 Bn 64.14 Bn - 34.98%
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -3.84%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 47.10%
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 140.88%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 140.88%
Dec 31, 2025 119.08%
Sep 30, 2025 55.52%
Jun 30, 2025 35.88%
Mar 31, 2025 60.88%
Dec 31, 2024 -29.07%
Sep 30, 2024 -16.33%
Jun 30, 2024 -70.71%
Mar 31, 2024 46.85%
Dec 31, 2023 10.30%
Sep 30, 2023 136.72%
Jun 30, 2023 -11.16%
Mar 31, 2023 26.62%
Dec 31, 2022 -36.47%
Sep 30, 2022 -4.20%
Jun 30, 2022 15.30%
Mar 31, 2022 -28.12%
Dec 31, 2021 101.36%
Sep 30, 2021 84.00%
Jun 30, 2021 41.82%
Mar 31, 2021 48.90%
Dec 31, 2020 44.25%
Sep 30, 2020 -34.29%
Jun 30, 2020 193.39%
Mar 31, 2020 -56.76%
Dec 31, 2019 132.14%
Sep 30, 2019 51.52%
Jun 30, 2019 45.17%
Mar 31, 2019 62.04%
Dec 31, 2018 7.77%
Sep 30, 2018 39.88%
Jun 30, 2018 77.98%
Mar 31, 2018 -30.86%
Dec 31, 2017 -59.40%
Sep 30, 2017 -15.28%
Jun 30, 2017 30.30%
Mar 31, 2017 -76.62%
Dec 31, 2016 30.20%
Sep 30, 2016 54.30%
Jun 30, 2016 148.74%
Mar 31, 2016 52.33%
Dec 31, 2015 43.23%
Sep 30, 2015 -22.16%
Jun 30, 2015 32.04%
Mar 31, 2015 26.07%
Dec 31, 2014 12.46%
Sep 30, 2014 46.08%
Jun 30, 2014 10.75%
Mar 31, 2014 -8.60%
Dec 31, 2013 -49.14%
Sep 30, 2013 11.42%
Jun 30, 2013 -41.69%
Mar 31, 2013 24.02%